KR20130018548A - Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide - Google Patents
Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide Download PDFInfo
- Publication number
- KR20130018548A KR20130018548A KR1020120082521A KR20120082521A KR20130018548A KR 20130018548 A KR20130018548 A KR 20130018548A KR 1020120082521 A KR1020120082521 A KR 1020120082521A KR 20120082521 A KR20120082521 A KR 20120082521A KR 20130018548 A KR20130018548 A KR 20130018548A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- methyl
- oxadiazol
- ethylcarbamoyl
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title claims abstract description 19
- 239000000651 prodrug Substances 0.000 title claims abstract description 19
- DPQHQVWUCNXFTJ-UHFFFAOYSA-N 5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazole-3-carboxamide Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C1=NOC(C)=N1 DPQHQVWUCNXFTJ-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 127
- -1 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-isopropyl Phenyl Chemical group 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 229910019142 PO4 Inorganic materials 0.000 claims description 24
- 239000010452 phosphate Substances 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000011777 magnesium Substances 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 230000001093 anti-cancer Effects 0.000 claims description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- AZVDNHQUPDKCEO-UHFFFAOYSA-N [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-phosphonooxy-4-propan-2-ylphenyl] dihydrogen phosphate Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(OP(O)(O)=O)=C(C(C)C)C=2)OP(O)(O)=O)=C1C1=NOC(C)=N1 AZVDNHQUPDKCEO-UHFFFAOYSA-N 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- SHMDGALAMSNXRJ-UHFFFAOYSA-L [K+].[K+].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 Chemical compound [K+].[K+].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 SHMDGALAMSNXRJ-UHFFFAOYSA-L 0.000 claims description 3
- MYHJLQOCYYFNLG-UHFFFAOYSA-L [Na+].[Na+].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 Chemical compound [Na+].[Na+].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 MYHJLQOCYYFNLG-UHFFFAOYSA-L 0.000 claims description 3
- GWWWNAKRFFANNF-UHFFFAOYSA-N bis(dimethylamino)phosphinic acid Chemical compound CN(C)P(O)(=O)N(C)C GWWWNAKRFFANNF-UHFFFAOYSA-N 0.000 claims description 3
- IDGLVVJBDHUPBX-UHFFFAOYSA-L calcium [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] phosphate Chemical compound [Ca++].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OP([O-])([O-])=O IDGLVVJBDHUPBX-UHFFFAOYSA-L 0.000 claims description 3
- FHQHXWZTJYRTHE-UHFFFAOYSA-L calcium [4-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-2-propan-2-ylphenyl] phosphate Chemical compound [Ca++].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(OP([O-])([O-])=O)cc1O FHQHXWZTJYRTHE-UHFFFAOYSA-L 0.000 claims description 3
- ZMRIQTAEQJLOAV-UHFFFAOYSA-L calcium [6-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-3-oxo-8-propan-2-yl-2,4-dioxa-3lambda5-phosphabicyclo[3.3.1]nona-1(8),5(9),6-trien-3-yl] phosphate Chemical compound [Ca+2].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 ZMRIQTAEQJLOAV-UHFFFAOYSA-L 0.000 claims description 3
- LRAADRPPWVSTOF-UHFFFAOYSA-L dipotassium [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] phosphate Chemical compound [K+].[K+].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OP([O-])([O-])=O LRAADRPPWVSTOF-UHFFFAOYSA-L 0.000 claims description 3
- RAVIUBFEDFWYAV-UHFFFAOYSA-L dipotassium [4-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-2-propan-2-ylphenyl] phosphate Chemical compound [K+].[K+].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(OP([O-])([O-])=O)cc1O RAVIUBFEDFWYAV-UHFFFAOYSA-L 0.000 claims description 3
- LEGYPMSJDWOPTC-UHFFFAOYSA-L disodium [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] phosphate Chemical compound [Na+].[Na+].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OP([O-])([O-])=O LEGYPMSJDWOPTC-UHFFFAOYSA-L 0.000 claims description 3
- SHFQJFSKRMZGMU-UHFFFAOYSA-L disodium [4-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-2-propan-2-ylphenyl] phosphate Chemical compound [Na+].[Na+].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(OP([O-])([O-])=O)cc1O SHFQJFSKRMZGMU-UHFFFAOYSA-L 0.000 claims description 3
- UJFLVGBOIDXLMP-UHFFFAOYSA-L magnesium [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] phosphate Chemical compound [Mg++].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OP([O-])([O-])=O UJFLVGBOIDXLMP-UHFFFAOYSA-L 0.000 claims description 3
- LOVNZEATULNORV-UHFFFAOYSA-L magnesium [4-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-2-propan-2-ylphenyl] phosphate Chemical compound [Mg++].CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(OP([O-])([O-])=O)cc1O LOVNZEATULNORV-UHFFFAOYSA-L 0.000 claims description 3
- ADRJRBUJJCIRTF-UHFFFAOYSA-L magnesium [6-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-3-oxo-8-propan-2-yl-2,4-dioxa-3lambda5-phosphabicyclo[3.3.1]nona-1(8),5(9),6-trien-3-yl] phosphate Chemical compound [Mg+2].CCNC(=O)C1=NOC(C=2C=3OP(=O)(OP([O-])([O-])=O)OC(C=3)=C(C(C)C)C=2)=C1C1=NOC(C)=N1 ADRJRBUJJCIRTF-UHFFFAOYSA-L 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- LPVKENZMCUWOFU-SQKCAUCHSA-N [2-[3-(ethylcarbamoyl)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-1,2-oxazol-5-yl]-5-hydroxy-4-propan-2-ylphenyl] (2S)-2,6-diaminohexanoate dihydrochloride Chemical compound Cl.Cl.CCNC(=O)c1noc(c1-c1noc(C)n1)-c1cc(C(C)C)c(O)cc1OC(=O)[C@@H](N)CCCCN LPVKENZMCUWOFU-SQKCAUCHSA-N 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 238000001727 in vivo Methods 0.000 abstract description 9
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 2
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- 101710113864 Heat shock protein 90 Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 9
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 8
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 108010006519 Molecular Chaperones Proteins 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000001177 diphosphate Substances 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000005431 Molecular Chaperones Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 0 CC(C)c(c(O*)c1)cc(-c([o]nc2*)c2-c2n[o]c(C)n2)c1O* Chemical compound CC(C)c(c(O*)c1)cc(-c([o]nc2*)c2-c2n[o]c(C)n2)c1O* 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 2
- 102100026973 Heat shock protein 75 kDa, mitochondrial Human genes 0.000 description 2
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102000000763 Survivin Human genes 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- 101150040313 Wee1 gene Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 150000008299 phosphorodiamidates Chemical class 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 150000008626 4-imidazolidinones Chemical class 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- FADKJNSSIWTVAI-SSDOTTSWSA-N CC([C@@H](CCCCN)N)=O Chemical compound CC([C@@H](CCCCN)N)=O FADKJNSSIWTVAI-SSDOTTSWSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 description 1
- 101000763352 Homo sapiens Heat shock protein 75 kDa, mitochondrial Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- FBVSXKMMQOZUNU-NSHDSACASA-N N2,N6-Bis{[(2-methyl-2-propanyl)oxy]carbonyl}lysine Chemical compound CC(C)(C)OC(=O)NCCCC[C@@H](C(O)=O)NC(=O)OC(C)(C)C FBVSXKMMQOZUNU-NSHDSACASA-N 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710204707 Transforming growth factor-beta receptor-associated protein 1 Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- PBMSWVPMRUJMPE-UHFFFAOYSA-N phthalylsulfathiazole Chemical class OC(=O)C1=CC=CC=C1C(=O)NC1=CC=C(S(=O)(=O)\N=C\2SC=CN/2)C=C1 PBMSWVPMRUJMPE-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinyl group Chemical group C1(O)=CC(O)=CC=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical group O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The present invention relates to novel compounds of formula (I). The compounds of formula (I) according to the invention are used as prodrugs of compounds of formula (II) which are parent compounds, which have valuable pharmacological properties.
The compound of formula (I) of the present invention has a solubility of 1,000 to 20,000 times or more compared to the compound of formula (II), which is a parent compound, and thus can increase bioavailability, and AUC 0 -120 min is 3 to 5 times and C max is greater than that of formula (II). It is absorbed in vivo at a concentration of 10 to 20 times, which greatly improves pharmacokinetic properties and can be used to treat various tumors, including ovarian cancer and gastric cancer.
Description
The present invention relates to compounds of formula (I)
<Formula I>
Where
R 1 and R 2 are both PO (OH) 2 or
Or R 1 Or when R 2 is hydrogen, the other R 1 or R 2 , PO (OH) 2 or And, M is Na +, K +, Mg 2 + or Ca 2 +, n is 1 or 2; n is a case of 1 M is Mg 2 + or Ca 2 +, and n is 2 days when M is Na + or K +.The compound of formula I is 5- (2,4-dihydroxy-5-isopropylphenyl) -ene-ethyl-4- () which is a compound of formula II which inhibits HSP90 activity disclosed in WO 2011/102660. It has been found that it can be used as a prodrug of 5-methyl-1,2,4-oxadiazol-3-yl) isoxazole-3-carboxamide.
<Formula II>
Prodrugs are biologically inactive derivatives of the parent drug molecule that in most cases require spontaneous or enzymatic modification in the body to release the active drug and have improved delivery properties over the parent drug molecule. It has been shown that in molecules with physicochemical properties and optimal structural coordination to elicit the desired therapeutic response at the target site, it is not necessary to have the best molecular morphology and properties for delivery to its ultimate point of action. Typically, only a minimal amount of the dose administered reaches the target site, and because most agents also interact with sites other than the target, inefficient delivery can result in unwanted side effects. This fact that the effect characteristics of delivery and in-situ differ for many drug molecules is that bio-reversible chemical induction of the drug, ie prodrug formation, often results in substantial improvement in the overall efficacy of the drug. It's the basic reason for achieving this. Prodrugs are designed to solve problems based on pharmacokinetics associated with parent drug molecules.
Recently, several types of bio-reversible derivatives have been developed for use in designing prodrugs. It is most common to use esters containing carboxyl or hydroxyl functional groups as types for drugs. Also, prodrug derivatives such as peptides and 4-imidazolidinones ( Drugs) of the Future , 1991, 16 (5), 443-458), prodrug derivatives of N-oxides (US Pat. No. 5,691,336) are known.
Molecular chaperone, on the other hand, is a generic term for proteins that temporarily form complexes with target proteins to promote the formation of functional higher order structures of proteins. Molecular chaperones help protein folding and association, and have the activity of inhibiting aggregation.
In general, exposure of cells to a variety of environmental disorders, including heat, alcohol, heavy metals and oxidative disorders, typically results in cell accumulation in many chaperones known as heat shock proteins (HSPs). These heat shock proteins (HSPs) are classified into HSP70, HSP90, and HSP27 according to the molecular weight. They protect cells against the initial impairment of impairment and enhance the maintenance and recovery induction of impaired resistance. In addition, any heat shock protein (HSPs) regulate folding, degradation, integration and function of important cellular proteins.
Some diseases of humans can be caused by the consequences of misfolded proteins. For example, proteins that are misfolded in Alzheimer's, prion and Huntington's disease can cause protein aggregation, leading to neurodegenerative diseases (Tytell M. and Hooper PL, Emerging Ther. Targets (2001) 3796). In addition, heat shock proteins (HSPs), especially HSP90, affect tumors through activation of various client proteins involved in cell proliferation or apoptosis. It has been reported that treatment of diseases through inhibition of chaperone function in such pathological symptoms is possible, and in particular inhibition of the function of HSP90 is useful for tumor treatment (Moloney A. and Workman P., Expert Opin. Biol. Ther. (2002), 2 (1), 3-24]; [Choisis et al, Drug Discovery Today (2004), 9, 881-888).
HSP90 (Heat Shock Protein 90) consists of HSP90α, HSP90β, GRP94 and HSP75 / TRAP1, which accounts for about 1-2% of total cell protein mass. It is in the form of a dimer in the cell and is associated with various proteins called co-chaperones. HSP90 restores original folding or protein aggregation through interaction with many proteins whose original folding has been modified by external stresses such as thermal shock (Smith DF et al., Pharmacological Rev. 1998), 50, 493-513). HSP90 also plays an important role as a buffer against mutations through modification of inaccurate protein folding caused by mutations (Rutherford and Lindquist, 1998). Under physiological conditions, HSP90 binds to a variety of client proteins (e. G., EGFR R / HER2, Src, Akt, Raf, MEK, Bcr- Abl, Flt-3, p53 in mutant form, Akt, And plays a role in stabilizing the stability of the sequences of the survivin, CDK4, Plk, Wee1, VEGF-R, FAK, HIF-1, hTert and c-Met etc. . These client proteins have the ability to proliferate in the absence of growth factors (EGFR-R / HER2, Src, Akt, Raf, MEK, Bcr-Abl, Flt-3, etc.); ii) the ability to evade apoptosis (mutant forms of p53, Akt, survivin, etc.); iii) insensitivity to the proliferation stop signal (Cdk4, Plk, Wee1, etc.); iv) the ability to activate angiogenesis (VEGF-R, FAK, HIF-1, Akt, etc.); v) the ability to propagate without any replication limitations (hTert, etc.); vi) involvement in the ability to evade new metastases (c-Met) (Hanahan D. and Weinberg RA, Cell (2002), 100, 57-70). Thus, inhibition of HSP90 activity can inhibit tumor formation by these client proteins.
Currently known HSP90 inhibitors are the first reported compounds of the ansamycin group, in particular geldanamycin and herbimycin A. X-ray studies have shown that geldanamycin binds to the ATP site of the N-terminal domain of HSP90, where geldanamycin inhibits chaperone ATPase activity (Prodromou C. et al, Cell (1997) 90, 65-75). Currently, NIH and KOSAN Biosciences are under clinical trials for 17AAG derived from geldanamycin.
Radicicol is a natural HSP90 inhibitor (Roe SM et al., J. Med Chem. (1999), 42, 260-66). Radicocor is the best in vitro HSP90 inhibitor to date, but it is difficult to use in vivo because it is metabolically labile to sulfur-containing nucleophiles. The natural HSP90 inhibitor novobiocin binds to other ATP sites in the C-terminal domain of the protein (Itoh H. et al, Biochem J. (1999), 343, 697-703). PU3 ([Chiosis et al, Chem. Biol. (2001), 8, 289-299), a purine-based compound, was reported as an HSP90 inhibitor as a low molecular HSP90 inhibitor.
(WO 2004/072080), phthalazole derivatives (WO 2004/050087), aryl isoxazole derivatives (WO 2004/052087), and the like, as well as 8-heteroaryl-6-phenylimidazo [ 2004/072051) and benzophenone derivatives (WO 2005/00778) have been reported as HSP90 inhibitors useful for treating tumors.
Most of the currently known HSP90 inhibitors inhibit ATPase activity by binding to the ATP site of the N-terminal domain of HSP90, preventing the co-chaperone build-up and allowing the tumor-associated client protein to function as a proteasome ). ≪ / RTI > The attractive reason for the development of HSP90 inhibitors for clinical use is the simultaneous inhibition of various tumors and their inducing proteins, resulting in a strong antitumor effect and selectivity for cancer and normal cells, thus achieving therapeutic benefits It is.
As cited herein, 5- (2,4-dihydroxy-5-isopropylphenyl) -ene-ethyl-4- (5-methyl-1,2,4- is a compound of formula II that inhibits HSP90 activity. Oxadiazol-3-yl) isoxazole-3-carboxamide is described in WO 2011/102660.
The compound of formula (II) shows good activity in in vitro tests, but is almost insoluble in water, thereby decreasing bioavailability, and extremely low pharmacokinetic parameters have many problems in drug development.
However, the compound of formula (I) has been shown to meet all requirements as a good prodrug. In particular, it improves superior solubility and excellent pharmacokinetic properties compared to the parent compound (II).
The present invention relates to 5- (2,4-dihydroxy-5-isopropylphenyl) -ene-ethyl-4- (5-methyl-1,2,4-oxa, a compound of formula II having an inhibitory effect on HSP90 activity. It is an object to provide prodrugs for improving the pharmacokinetic properties of diazol-3-yl) isoxazole-3-carboxamide.
In order to achieve the above object, the present invention provides a novel compound represented by the following formula (I).
<Formula I>
Where
R 1 and R 2 are both PO (OH) 2 or
Or R 1 Or when R 2 is hydrogen, the other R 1 or R 2 , PO (OH) 2 or And, M is Na +, K +, Mg 2 + or Ca 2 +, n is 1 or 2; n is a case of 1 M is Mg 2 + or Ca 2 +, and n is 2 days when M is Na + or K +.Particularly preferred examples of the compound of formula I according to the present invention are as follows.
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3- Phenylene bis (dihydrogen phosphate); (I-1)
(S) -2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy- 4-isopropylphenyl 2,6-diaminohexanoate dihydrochloride; (I-2)
Sodium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3 -Phenylene diphosphate; (I-3)
2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-isopropyl Phenyl dihydrogen phosphate; (I-4)
Sodium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-iso Propylphenyl phosphate; (I-5)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-isopropyl Phenyl dihydrogen phosphate; (I-6)
Sodium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-iso Propylphenyl phosphate; (I-7)
Potassium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3 -Phenylene diphosphate; (I-8)
Potassium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-iso Propylphenyl phosphate; (I-9)
Potassium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-iso Propylphenyl phosphate; (I-10)
Calcium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3 -Phenylene diphosphate; (I-11)
Calcium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-iso Propylphenyl phosphate; (I-12)
Calcium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-iso Propylphenyl phosphate; (I-13)
Magnesium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3 -Phenylene diphosphate; (I-14)
Magnesium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-iso Propylphenyl phosphate; (I-15)
Magnesium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-iso Propylphenyl phosphate; (I-16)
The present invention also provides a process for preparing the compound of formula (I).
The preparation method of the compound of formula I according to the present invention is shown in Scheme 1 below.
<Reaction Scheme 1>
The compounds of formula (I) of the present invention may be prepared by a series of processes from the compound of formula (II), the parent drug, as shown in Scheme 1 above.
The manufacturing method will be described in more detail as follows.
1) Preparation of Compound of Formula II
Formula II compounds used as starting materials may be prepared by methods known from WO 2011/102660.
2) Preparation of Compound of Formula (I)
First, an intermediate compound having introduced protected lysine was esterified by esterification of the compound of formula II with methylene chloride in position 4 with Boc (tert-butoxycarbonyl), and then deprotected with hydrochloric acid to give R 1 or R 2
The following formula (Ia) compound can be prepared.<Formula Ia>
Where
R 1 and R 2 are differently selected hydrogen or
to be.The following scheme shows an example according to the preparation method.
Second, a bis (tetramethylphosphorodiamidate) intermediate compound is synthesized by substituting the compound of formula (II) with tetramethylphosphorodiamid chloride in a water or dioxane solvent, followed by hydrolysis using trifluoroacetic acid or hydrochloric acid. The decomposition reaction may produce the following general formula (Ib) compound wherein R 1 and / or R 2 is PO (OH) 2 .
<Formula Ib>
Where
R 1 and R 2 are both PO (OH) 2 or hydrogen or PO (OH) 2 selected differently.
The following scheme shows one embodiment of the preparation method.
Third, the compound of Formula Ib is reacted with an inorganic base selected from NaOH, KOH, Ca (OH) 2 or Mg (OH) 2 to give R 1 and / or R 2
A compound of formula (Ic) may be prepared. Formula Ic compounds that are salt compounds are included within the scope of the compounds of Formula I of the present invention.<Formula Ic>
Where
R 1 and R 2 are both
Or hydrogen selected differently or ; M is Na +, K +, Mg 2 + or Ca 2 +, n is 1 or 2; n is a case of 1 M is Mg 2 + or Ca 2 +, and n is 2 days when M is Na + or K +.The following scheme shows one embodiment of the preparation method.
As mentioned above, the compounds of formula I according to the invention can be used as prodrugs of compounds of formula II, which have valuable pharmacological properties.
These compounds were then investigated according to the tests given in the present invention. Evidence that the compound of formula I can be used as a prodrug of a compound of formula II, which is the parent compound, is presented according to the description given herein below.
The compound of formula (I) of the present invention has a solubility of 1,000 to 20,000 times or more compared to the compound of formula (II), which is a parent compound, and thus can increase bioavailability, and AUC 0 -120 min is 3 to 5 times and C max is greater than that of formula (II). It can be absorbed in vivo at a concentration of 10-20 folds and greatly improve pharmacokinetic properties.
Formula II compounds, which are parent compounds, are diseases that respond to inhibition of HSP90 activity, i.e. immunosuppression or inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, type 1 diabetes, lupus, psoriasis and inflammation and enteropathies, viral diseases; Diabetic retinopathy, angioma and endometriosis; Or protection of normal cells against chemotherapy-induced toxicity; Hypoxia due to elevation of HSP70 in the heart and brain - diseases in which HSP90 activity is implicated, including those used for protection from ischemic injury; It is suitable for treating Scrapie / CJD, Huntington or Alzheimer's disease. Especially for the treatment of cancer.
Therefore, the compound of formula (I) according to the present invention is a prodrug in which several functional groups are introduced to the resorcinol group of the compound of formula (II), which is a parent compound, and shows effective anticancer activity against various carcinomas.
The anticancer pharmaceutical composition of the present invention may be administered by any convenient route, for example, oral, parenteral, oral, sublingual, nasal, rectal or subcutaneous, including the above formula (I) compound and a pharmaceutically acceptable excipient. It can be formulated.
In addition, the dosage or dosage of the pharmaceutical composition according to the present invention varies depending on the weight, age, sex, health condition, diet, time of administration, administration method, excretion rate and severity of the patient, the specific configuration The dose of the drug may be divided into one or several times 0.1 to 1,000 mg of the compound of formula I on an adult basis.
The present invention provides novel compounds of formula (I). The compounds of formula (I) according to the invention are used as prodrugs of compounds of formula (II) which are parent compounds, which have valuable pharmacological properties.
The compound of formula (I) of the present invention has a solubility of 1,000 to 20,000 times or more compared to the compound of formula (II), which is a parent compound, and thus can increase bioavailability, and AUC 0 -120 min is 3 to 5 times and C max is greater than that of formula (II). It is absorbed in vivo at a concentration of 10 to 20 times, which greatly improves pharmacokinetic properties and can be used to treat various tumors, including ovarian cancer and gastric cancer.
The present invention can be described in more detail through the following examples and experimental examples, but these are merely intended to illustrate the present invention, but the present invention is not limited thereto.
<Example 1> Synthesis of 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl -1,3 -phenylene Preparation of Bis (Dihydrogen Phosphate) (I-1)
Step 1: 4- (3- ( ethylcarbamoyl ) -4- (5- methyl -1,2,4 -oxadiazol- 3 - yl) isoxazol- 5 - yl) -6 -isopropyl- 1 , 3 -phenylene Preparation of bis (tetramethyl-dimethyl phosphorothioate amidate)
5- (2,4-Dihydroxy-5-isopropylphenyl) -N-ethyl-4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazole-3-car Copyamide (250 mg, 0.67 mmol) was dissolved in methylene chloride (7 mL), and then tetramethylphosphorodiamid chloride (0.35 mL, 2.35 mmol), 4- (dimethylamino) pyridine (41 mg, 0.34 mmol) was added sequentially. 1,8-diazabicyclo [5.4.0] -undec-7-ene (0.25 mL, 1.68 mmol) was added dropwise, and the reaction solution was stirred overnight at room temperature. The reaction was terminated with saturated aqueous ammonium chloride solution and extracted with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure, and the obtained residue was separated by column chromatography to obtain the intermediate compound 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) eye. Soxazol-5-yl) -6-isopropyl-1,3-phenylene bis (tetramethylphosphorodiamidate) (428 mg, 0.67 mmol, 99%) was obtained.
1 H-NMR (400 MHz, CDCl 3 ) δ 7.54 (s, 1H), 7.44 (s, 1H), 6.97 (br t, 1H), 3.49 (m, 2H), 3.27 (sept, 1H), 2.80 ( s, 6H), 2.77 (s, 6H), 2.66 (s, 6H), 2.63 (s, 6H), 2.61 (s, 3H), 1.26 (t, 3H), 1.19 (d, 6H)
Step 2: 4- (3- ( ethylcarbamoyl ) -4- (5- methyl -1,2,4 -oxadiazol- 3 - yl) isoxazol- 5 - yl) -6 -isopropyl- 1 , 3 -phenylene Preparation of Bis (Dihydrogen Phosphate)
The intermediate compound (428 mg, 0.67 mmol) prepared in step 1 was dissolved in a mixed solvent of trifluoroacetic acid (1.8 mL) and water (0.2 mL), and then stirred at room temperature overnight. All solvents were removed under reduced pressure, and the obtained residue was diluted with methanol. The insoluble material produced at this time was removed by filtration, and the filtrate was concentrated under reduced pressure. The obtained residue was diluted with water, washed with ethyl acetate and the aqueous layer was concentrated under reduced pressure. The material thus obtained was dissolved in water and passed through a Dowex® 50WX4 cation exchange resin to remove by-products and dried in vacuo to afford the target compound (250 mg, 0.47 mmol, 70%).
1 H-NMR (400 MHz, D 2 O) δ 7.49 (s, 1H), 7.22 (s, 1H), 3.35 (q, 2H), 3.24 (sept, 1H), 2.50 (s, 3H), 1.14 ( t, 3H), 1.11 (d, 6H)
<Example 2> (S) -2- (3- ( ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) - 5 -hydroxy -4 -isopropylphenyl 2,6 -diaminohexanoate Preparation of Dihydrochloride (I-2)
Step 1: (S) -2- (3- ( ethylcarbamoyl ) -4- (5- methyl -1,2,4 -oxadiazol- 3 - yl) isoxazol- 5 - yl) -5- hydroxy-4-isopropyl-phenyl-2,6-bis((tert-butoxy carbonyl) amino) hexanoate Preparation of
5- (2,4-Dihydroxy-5-isopropylphenyl) -N-ethyl-4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazole-3-car Copyamide (138 mg, 0.37 mmol) was dissolved in DMF (3.0 mL) to dissolve 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (248 mg, 1.29 mmol) and 4- (dimethylamino) pyridine. (22 mg, 0.19 mmol) and Boc-Lys (Boc) -OH (384 mg, 1.11 mmol) were added dropwise, followed by stirring at room temperature for 12 hours. The residue obtained by concentrating the reaction solution was separated by column chromatography to obtain an intermediate compound (S) -2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazole-3- I) isoxazol-5-yl) -5-hydroxy-4-isopropylphenyl 2,6-bis ((tert-butoxycarbonyl) amino) hexanoate (200 mg, 0.19 mmol, 53%) Got.
1 H-NMR (400 MHz, CDCl 3 ) δ 7.65 (s, 1H), 7.43 (s, 1H), 5.21 (br, 2H), 4.55 (br, 2H), 4.40 (br, 2H), 3.48 (m , 2H), 3.18-3.06 (m, 3H), 2.67 (s, 3H), 1.98 (br, 2H), 1.84 (br, 1H), 1.48 (m, 18H), 1.28-1.23 (m, 9H)
Step 2: (S) -2- (3- ( ethylcarbamoyl ) -4- (5- methyl -1,2,4 -oxadiazol- 3 - yl) isoxazol- 5 - yl) -5- Hydroxy -4 -isopropylphenyl 2,6 -diaminohexanoate Preparation of dihydrochloride
The intermediate compound (50 mg, 0.05 mmol) prepared in step 1 was dissolved in 4.0M dioxane solution (0.4 mL, 1.46 mmol) in hydrochloric acid in CH 3 CN (0.5 mL), and stirred at room temperature for 12 hours. The reaction solution was concentrated to obtain the target compound (28 mg, 0.05 mmol, 99%).
1 H-NMR (400 MHz, D 2 O) δ 7.85 (s, 1H), 7.58 (s, 1H), 4.55 (m, 1H), 4.31 (m, 1H), 3.44 (m, 2H), 3.41 ( m, 3H), 3.13 (m, 1H), 3.04-2.95 (m, 5H), 2.61 (s, 3H), 1.82 (m, 2H), 1.73 (m, 1H), 1.28-1.21 (m, 9H)
<Example 3> sodium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl Propyl -1,3 -phenylene Preparation of Diphosphate (I-3)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3- Phenylene bis (dihydrogen phosphate) (4.90g, 9.20mmol) was dissolved in water (350ml) and 1N NaOH (36.59ml, 36.59mmol) was added dropwise, followed by stirring at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain the target compound (5.63 g, 9.08 mmol, 99%).
1 H-NMR (400 MHz, D 2 O) δ 7.40 (s, 1H), 7.33 (s, 1H), 3.46 (q, 2H), 3.38 (m, 1H), 2.63 (s, 3H), 1.26 ( t, 3H), 1.16 (d, 6H)
<Example 4> 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy- -4 -isopropylphenyl Dihydrogen Preparation of Phosphate (I-4)
Step 1: 5- (4- ( ethoxymethoxy ) -2 -hydroxy -5 -isopropylphenyl ) -N-ethyl-4- (5- methyl -1,2,4 -oxadiazole- 3- I) Preparation of Isoxazole - 3 -carboxamide
5- (2,4-Dihydroxy-5-isopropylphenyl) -N-ethyl-4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazole-3-car Radiantamide (5.00 g, 13.4 mmol) was dissolved in acetone (300 mL), and then added dropwise to triethylamine (2.25 mL, 16.1 mmol) and ethoxymethyl chloride (1.31 mL, 14.1 mmol) at 0 ° C. overnight. Stirred. Concentrated under reduced pressure to remove the solvent, extracted with ethyl acetate and saturated aqueous sodium chloride solution, the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the residue by column chromatography to obtain the intermediate compound 5- (2- (ethoxymeth) Methoxy) -4-hydroxy-5-isopropylphenyl) -N-ethyl-4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazole-3-carboxamide ( 1.40 g, 3.26 mmol, 24.3%).
1 H-NMR (400 MHz, CDCl 3 ) δ 7.44 (s, 1H), 6.99 (brt, 1H), 6.67 (s, 1H), 5.87 (s, 1H), 4.90 (s, 2H), 3.54-3.45 (m, 4H), 3.10 (sept, 1H), 2.60 (s, 3H), 1.38-1.21 (m, 12H).
Step 2: 5- ( ethoxymethoxy ) -2- (3- ( ethylcarbamoyl ) -4- (5- methyl -1,2,4 -oxadiazol- 3-yl) isoxazole- 5 Yl) -4 -isopropylphenyltetramethyl Preparation of Phosphorodiamidates
The intermediate compound (1.40 g, 3.26 mmol) prepared in step 1 was dissolved in methylene chloride (40 mL), and then 4- (dimethylamino) pyridine (199 mg, 1.63 mmol) and 1,8-diazaby Cyclo [5.4.0] -undec-7-ene (0.56 mL, 3.91 mmol) and tetramethylphosphorodiamid chloride (0.56 mL, 3.91 mmol) were added dropwise in order, and the reaction solution was stirred overnight at room temperature. The reaction was terminated with saturated aqueous ammonium chloride solution and extracted with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure, and the obtained residue was separated by column chromatography to obtain the intermediate compound 5- (ethoxymethoxy) -2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4- Oxadiazol-3-yl) isoxazol-5-yl) -4-isopropylphenyltetramethyl phosphorodiamidate (1.82 g, 3.23 mmol, 99%) was obtained.
1 H-NMR (400 MHz, CDCl 3 ) δ 7.52 (s, 1H), 7.23 (s, 1H), 6.98 (brt, 1H), 4.93 (s, 2H), 3.52-3.43 (m, 4H), 3.26 (sept, 1H), 2.77 (s, 6H), 2.74 (s, 6H), 2.60 (s, 3H), 1.27-1.22 (m, 9H), 1.18 (t, 3H)
Step 3: 2- (3- ( ethylcarbamoyl ) -4- (5- methyl -1,2,4 -oxadiazol- 3 - yl) isoxazol- 5 - yl) -5 -hydroxy- 4 - isopropyl phenyl Dihydrogen Preparation of Phosphate
The intermediate compound (1.82g, 3.23mmol) prepared in step 2 was dissolved in 1,4-dioxane (100ml), 12N hydrochloric acid (100ml) was added dropwise and stirred at room temperature for 3 hours. Concentration under reduced pressure removed the solvent and hydrochloric acid, and the obtained residue was separated by reverse phase chromatography to obtain the target compound (1.10 g, 2.42 mmol, 75%).
1 H-NMR (400 MHz, D 2 O) δ 7.33 (s, 1H), 6.79 (s, 1H), 3.30 (q, 2H), 3.07 (sept, 1H), 2.47 (s, 3H), 1.10 ( t, 3H), 1.04 (d, 6H)
<Example 5> sodium 2 (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy Preparation of Roxy -4 - isoisophenyl Phosphate (I-5)
2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-isopropyl Phenyl dihydrogen phosphate (60 mg, 0.13 mmol) was dissolved in water (4.8 mL), 1N NaOH (0.26 mL, 0.26 mmol) was added dropwise, followed by stirring at room temperature for 30 minutes. Concentration under reduced pressure removed the solvent to obtain the target compound (66 mg, 0.13 mmol, 99%).
1 H-NMR (400 MHz, D 2 O) δ 7.22 (s, 1H), 6.96 (s, 1H), 3.33 (q, 2H), 3.06 (sept, 1H), 2.49 (s, 3H), 1.12 ( t, 3H), 1.02 (d, 6H)
<Example 6> Synthesis of 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy- -2 -isopropylphenyl Dihydrogen Preparation of Phosphate (I-6)
Step 1: 5- (2- ( ethoxymethoxy ) -4 -hydroxy -5 -isopropylphenyl ) -N-ethyl-4- (5- methyl -1,2,4 -oxadiazole- 3- I) Preparation of Isoxazole - 3 -carboxamide
5- (2,4-Dihydroxy-5-isopropylphenyl) -N-ethyl-4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazole-3-car Radiantamide (5.00 g, 13.4 mmol) was dissolved in acetone (300 mL), and then added dropwise to cesium carbonate (5.25 g, 16.1 mmol), ethoxymethyl chloride (1.31 mL, 14.1 mmol) at 0 ° C., and then stirred overnight. It was. Concentrated under reduced pressure to remove the solvent, extracted with ethyl acetate and saturated aqueous sodium chloride solution, the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the residue by column chromatography to obtain the intermediate compound 5- (2- (ethoxymeth) Methoxy) -4-hydroxy-5-isopropylphenyl) -N-ethyl-4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazole-3-carboxamide ( 3.02 g, 7.01 mmol, 52.3%).
1 H-NMR (400 MHz, CDCl 3 ) δ 7.42 (s, 1H), 6.64 (s, 1H), 5.85 (s, 1H), 4.89 (s, 2H), 3.52-3.44 (m, 4H), 3.15 ~ 3.09 (m, 1H), 2.60 (s, 3H), 1.64 (s, 3H), 1.35-1.05 (m, 16H), 0.90-0.82 (m, 2H).
Step 2: 5- ( ethoxymethoxy ) -4- (3- ( ethylcarbamoyl ) -4- (5- methyl -1,2,4 -oxadiazol- 3-yl) isoxazole- 5 Yl) -2 -isopropylphenyltetramethyl Preparation of Phosphorodiamidates
The intermediate compound (3.02 g, 7.01 mmol) prepared in step 1 was dissolved in methylene chloride (80 mL), and then 4- (dimethylamino) pyridine (428 mg, 3.50 mmol) and 1,8-diazabile were added thereto. Cyclo [5.4.0] -undec-7-ene (1.21 mL, 8.41 mmol) and tetramethylphosphorodiamid chloride (1.21 mL, 8.41 mmol) were added dropwise in order, followed by stirring at room temperature overnight. The reaction was terminated with saturated aqueous ammonium chloride solution and extracted with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure, and the obtained residue was separated by column chromatography to obtain the intermediate compound 5- (ethoxymethoxy) -4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4- Oxadiazol-3-yl) isoxazol-5-yl) -2-isopropylphenyltetramethyl phosphorodiamidate (3.95 g, 6.99 mmol, 99%) was obtained.
1 H-NMR (400 MHz, CDCl 3 ) δ 7.50 (s, 1H), 7.24 (s, 1H), 6.96 (brt, 1H), 4.95 (s, 2H), 3.52-3.44 (m, 4H), 3.26 (sept, 1H), 2.78 (s, 6H), 2.74 (s, 6H), 2.60 (s, 3H), 1.27-1.22 (m, 9H), 1.17 (t, 3H)
Step 3: 4- (3- ( ethylcarbamoyl ) -4- (5- methyl -1,2,4 -oxadiazol- 3 - yl) isoxazol- 5 - yl) -5 -hydroxy- 2 Oh isopropyl page carbonyl die hydrogen Preparation of Phosphate
The intermediate compound (3.95 g, 6.99 mmol) prepared in step 2 was dissolved in 1,4-dioxane (200 mL), and 12N hydrochloric acid (200 mL) was added dropwise, followed by stirring at room temperature for 3 hours. Concentration under reduced pressure removed the solvent and hydrochloric acid, and the obtained residue was separated by reverse phase chromatography to obtain the target compound (2.53 g, 5.59 mmol, 80%).
1 H-NMR (400 MHz, D 2 O) δ 7.30 (s, 1H), 6.76 (s, 1H), 3.26 (q, 2H), 3.08 (sept, 1H), 2.46 (s, 3H), 1.08 ( t, 3H), 1.00 (d, 6H)
<Example 7> sodium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy Preparation of Roxy -2 - isoisophenyl Phosphate (I-7)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-isopropyl Phenyl dihydrogen phosphate (177 mg, 0.39 mmol) was dissolved in water (3.91 mL), 1N NaOH (0.78 mL, 0.78 mmol) was added dropwise, followed by stirring at room temperature for 30 minutes. Concentration under reduced pressure to remove the solvent, the residue obtained was dissolved in water and freeze-dried to obtain the target compound (196 mg, 0.39 mmol, 99%).
1 H-NMR (400 MHz, D 2 O) δ 7.27 (s, 1H), 6.87 (s, 1H), 3.27 (q, 2H), 3.14 (sept, 1H), 2.47 (s, 3H), 1.07 ( t, 3H), 1.01 (d, 6H)
<Example 8> Potassium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl Propyl -1,3 -phenylene Preparation of Diphosphate (I-8)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3- Phenylene bis (dihydrogen phosphate) (1.00 g, 1.87 mmol) was dissolved in water (70 mL), 1N KOH (7.46 mL, 7.46 mmol) was added dropwise, and stirred at room temperature for 30 minutes. The reaction solution was concentrated to obtain the target compound (1.11 g, 1.63 mmol, 87%).
1 H-NMR (400 MHz, D 2 O) δ 7.40 (s, 1H), 7.33 (s, 1H), 3.46 (q, 2H), 3.38 (m, 1H), 2.63 (s, 3H), 1.26 ( t, 3H), 1.16 (d, 6H)
<Example 9> potassium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy Preparation of Roxy -4 - isoisophenyl Phosphate (I-9)
2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-isopropyl Phenyl dihydrogen phosphate (60 mg, 0.13 mmol) was dissolved in water (4.8 mL), 1N KOH (0.26 mL, 0.26 mmol) was added dropwise, followed by stirring at room temperature for 30 minutes. Concentration under reduced pressure removed the solvent to obtain the target compound (64 mg, 0.12 mmol, 94%).
1 H-NMR (400 MHz, D 2 O) δ 7.22 (s, 1H), 6.96 (s, 1H), 3.33 (q, 2H), 3.06 (sept, 1H), 2.49 (s, 3H), 1.12 ( t, 3H), 1.02 (d, 6H)
<Example 10> Potassium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy Roxy -2 -isopropylphenyl Preparation of Phosphate (I-10)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-isopropyl Phenyl dihydrogen phosphate (150 mg, 0.33 mmol) was dissolved in water (3.31 mL), 1N KOH (0.66 mL, 0.66 mmol) was added dropwise, and stirred at room temperature for 30 minutes. After concentration under reduced pressure to remove the solvent, the obtained residue was dissolved in water and freeze-dried to obtain the target compound (162 mg, 0.30 mmol, 93%).
1 H-NMR (400 MHz, D 2 O) δ 7.27 (s, 1H), 6.87 (s, 1H), 3.27 (q, 2H), 3.14 (sept, 1H), 2.47 (s, 3H), 1.07 ( t, 3H), 1.01 (d, 6H)
<Example 11> calcium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl Propyl -1,3 -phenylene Preparation of Diphosphate (I-11)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3- Phenylene bis (dihydrogen phosphate) (1.00 g, 1.87 mmol) was dissolved in water (70 mL), and 1N Ca (OH) 2 (3.73 mL, 3.73 mmol) was added dropwise, followed by stirring at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain the target compound (1.01 g, 1.66 mmol, 89%).
1 H-NMR (400 MHz, D 2 O) δ 7.40 (s, 1H), 7.33 (s, 1H), 3.46 (q, 2H), 3.38 (m, 1H), 2.63 (s, 3H), 1.26 ( t, 3H), 1.16 (d, 6H)
<Example 12> Calcium 2 - (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy Roxy -4 -isopropylphenyl Preparation of Phosphate (I-12)
2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-isopropyl Phenyl dihydrogen phosphate (60 mg, 0.13 mmol) was dissolved in water (4.8 mL), 1N Ca (OH) 2 (0.13 mL, 0.13 mmol) was added dropwise, and stirred at room temperature for 30 minutes. Concentration under reduced pressure removed the solvent to obtain the target compound (52 mg, 0.11 mmol, 82%).
1 H-NMR (400 MHz, D 2 O) δ 7.22 (s, 1H), 6.96 (s, 1H), 3.33 (q, 2H), 3.06 (sept, 1H), 2.49 (s, 3H), 1.12 ( t, 3H), 1.02 (d, 6H)
<Example 13> calcium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy Roxy -2 -isopropylphenyl Preparation of Phosphate (I-13)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-isopropyl Phenyl dihydrogen phosphate (100 mg, 0.22 mmol) was dissolved in water (2.2 mL), 1N Ca (OH) 2 (0.22 mL, 0.22 mmol) was added dropwise, and stirred at room temperature for 30 minutes. Concentration under reduced pressure to remove the solvent, the residue obtained was dissolved in water and freeze-dried to obtain the target compound (96 mg, 0.19 mmol, 89%).
1 H-NMR (400 MHz, D 2 O) δ 7.27 (s, 1H), 6.87 (s, 1H), 3.27 (q, 2H), 3.14 (sept, 1H), 2.47 (s, 3H), 1.07 ( t, 3H), 1.01 (d, 6H)
<Example 14> magnesium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl Propyl -1,3 -phenylene Preparation of Diphosphate (I-14)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3- Phenylene bis (dihydrogen phosphate) (100 mg, 0.187 mmol) was dissolved in water (7 mL), and 1 N Mg (OH) 2 (0.37 mL, 0.37 mmol) was added dropwise, followed by stirring at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure to obtain the target compound (79.8 mg, 0.14 mmol, 74%).
1 H-NMR (400 MHz, D 2 O) δ 7.40 (s, 1H), 7.33 (s, 1H), 3.46 (q, 2H), 3.38 (m, 1H), 2.63 (s, 3H), 1.26 ( t, 3H), 1.16 (d, 6H)
<Example 15> magnesium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy Roxy -4 -isopropylphenyl Preparation of Phosphate (I-15)
2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-isopropyl Phenyl dihydrogen phosphate (40 mg, 0.087 mmol) was dissolved in water (3.2 mL), 1 N Mg (OH) 2 (0.087 mL, 0.087 mmol) was added dropwise, followed by stirring at room temperature for 30 minutes. Concentration under reduced pressure removed the solvent to obtain the target compound (28.5 mg, 0.06 mmol, 82%).
1 H-NMR (400 MHz, D 2 O) δ 7.22 (s, 1H), 6.96 (s, 1H), 3.33 (q, 2H), 3.06 (sept, 1H), 2.49 (s, 3H), 1.12 ( t, 3H), 1.02 (d, 6H)
<Example 16> magnesium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy Roxy -2 -isopropylphenyl Preparation of Phosphate (I-16)
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-isopropyl Phenyl dihydrogen phosphate (62 mg, 0.14 mmol) was dissolved in water (1.36 mL), 1N Mg (OH) 2 (0.14 mL, 0.14 mmol) was added dropwise, and stirred at room temperature for 30 minutes. The mixture was concentrated under reduced pressure to remove the solvent, and then the obtained residue was dissolved in water and freeze dried to obtain the target compound (42 mg, 0.11 mmol, 81%).
1 H-NMR (400 MHz, D 2 O) δ 7.27 (s, 1H), 6.87 (s, 1H), 3.27 (q, 2H), 3.14 (sept, 1H), 2.47 (s, 3H), 1.07 ( t, 3H), 1.01 (d, 6H)
< Experimental Example 1> Solubility test
In order to determine whether the compound of formula (I) of the present invention has better solubility than the parent compound (II), the solubility was measured and shown in Table 1.
The compound of formula (I) and the parent compound of formula (II) according to the present invention were put into water, respectively, and shaken vigorously for 30 seconds every 5 minutes at 20 ± 5 ° C. to confirm the degree of melting within 30 minutes.
As can be seen in Table 1, the amount of water required to dissolve 1 g of the compound of formula II, the parent compound, is 10,000 ml or more. According to the KP solubility evaluation, the compound of formula II is a poorly soluble drug that is hardly soluble in water. The compound of formula (I) according to the invention exhibited a solubility in water of 1,000 to 20,000 times higher than that of the compound of formula (II), so that the solubility in water was very good solubility of the compound of formula (I) .
Accordingly, the compound of formula (I) according to the present invention is expected to exhibit a high bioavailability as well as greatly improved physicochemical properties to be easily formulated by showing a very good solubility compared to the formula (II) compound of the parent compound.
< Experimental Example 2> Pharmacokinetic Tests in Mice
A pharmacokinetic test was conducted to determine whether the compound of formula I according to the present invention is converted into a compound of formula II (the parent drug) in vivo and whether the concentration of the compound of formula II (the parent drug) in the blood is increased. The compound of formula I according to the present invention was orally administered to Balb / c male mice at a dose of 10 ml / kg using an oral intubation tube.
Blood samples were collected at 10, 20, 30, 60, and 120 minutes after administration on the basis of time of administration and collected in a lithium heparin coated tube. The blood thus obtained was centrifuged and the supernatant (plasma) was separated and stored frozen until analysis.
Plasma samples were prepared by liquid extraction with ethyl acetate after the addition of internal standards. Quantitative analysis was carried out by LC-MS / MS method under conditions specific to the selected compound, and analysis of the compound of formula (I) and the parent compound (II) according to the present invention was carried out on test animals to which the selected compound was administered. Pharmacokinetic parameters were obtained through WinNon Lin® non-compartmental analysis software and the results are shown in Table 2.
As can be seen in Table 2, the parent compound is a compound of formula II is AUC 0 -120 min Although the area under the plasma concentration-time curve was 33,529 ng · min · l −1 , and the C max (the highest concentration in the blood) was 420 ng / ml, the compound of formula I according to the present invention The compound of formula I according to the present invention is absorbed in vivo at a concentration of 3 to 5 times AUC 0 -120 min and 10 to 20 times C max compared to the dosage and molecular weight It can be seen that the pharmacokinetic properties are greatly improved by showing very good pharmacokinetics compared to the compound of formula II.
Therefore, the compounds of formula I according to the present invention can be usefully used as anticancer pharmaceutical compositions as prodrugs of compounds of formula II.
< Experimental Example 3> In vivo anticancer activity measurement test
In order to evaluate the anticancer efficacy of the compound of formula I according to the present invention in vivo, the following test was carried out.
A2780 ovarian cancer cell line was cultured at 8 x 10 < 6 > concentration Balb / c After xenograft subcutaneously into female nude mice, mice with tumors of appropriate size (50-200 mm 3) were selected as test animals (n = 3-6 / test group). Formula I compounds (I-1, I-2, I-3, I-7) according to the present invention were dissolved in sterile materials and administered orally at a dose of 200 mg / kg, respectively. Only the base itself was orally administered to the control group. The dosing schedule was five consecutive days (Monday to Friday) once a day for two weeks.
Body weight and tumor size of the test animals was twice measured a week, especially in tumor size is a measurement of the long axis (l) and the speed (w) of the tumor with a digital caliper, and [l × w 2] / 2 (㎣) Calculated by the formula. After calculating the average tumor size of each group, the size change value of the test group was divided by the control group size change value, multiplied by 100 and subtracted from 100% to obtain the tumor growth inhibition rate (% TGI) is shown in Table 3. Expressed as an expression:
Tumor growth inhibition rate (% TGI) = (1- drug treatment / control) x 100
As can be seen in Table 3, the compounds according to the invention showed a high tumor growth inhibition rate (% TGI).
Therefore, from the above Experimental Examples 1, 2 and 3, the new compound of the general formula (I) according to the present invention has solubility of 1,000 to 20,000 times or more than the parent compound of the general formula (II), and AUC 0 compared to the dosage and molecular weight of the compound of the general formula (II) . It can be seen that it can be very useful as an anticancer pharmaceutical composition by absorbing in vivo at a concentration of -120 min increased 3 to 5 times and C max 10 to 20 times.
Claims (11)
<Formula I>
In this formula,
R 1 and R 2 are both PO (OH) 2 or Or R 1 Or when R 2 is hydrogen, another R 1 Or R 2 is , PO (OH) 2 or and, M is Na +, K +, Mg 2 + or Ca 2 +, n is 1 or 2; when n is 1 where M is Mg 2 + or Ca 2 +, when n is 2 and M is Na + or K +.
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3- Phenylene bis (dihydrogen phosphate);
(S) -2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy- 4-isopropylphenyl 2,6-diaminohexanoate dihydrochloride;
Sodium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3 -Phenylene diphosphate;
2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-isopropyl Phenyl dihydrogen phosphate;
Sodium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-iso Propylphenyl phosphate;
4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-isopropyl Phenyl dihydrogen phosphate;
Sodium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-iso Propylphenyl phosphate;
Potassium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3 -Phenylene diphosphate;
Potassium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-iso Propylphenyl phosphate;
Potassium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-iso Propylphenyl phosphate;
Calcium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3 -Phenylene diphosphate;
Calcium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-iso Propylphenyl phosphate;
Calcium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-iso Propylphenyl phosphate;
Magnesium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -6-isopropyl-1,3 -Phenylene diphosphate;
Magnesium 2- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-4-iso Propylphenyl phosphate;
Magnesium 4- (3- (ethylcarbamoyl) -4- (5-methyl-1,2,4-oxadiazol-3-yl) isoxazol-5-yl) -5-hydroxy-2-iso Propylphenyl Phosphate
<Formula II>
<Formula II>
<Formula II>
<Formula Ib>
In this formula,
R 1 and R 2 are both PO (OH) 2 or hydrogen or PO (OH) 2 selected differently.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2012/006043 WO2013015661A2 (en) | 2011-07-28 | 2012-07-27 | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110074867 | 2011-07-28 | ||
KR1020110074867 | 2011-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130018548A true KR20130018548A (en) | 2013-02-25 |
Family
ID=47897259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120082521A KR20130018548A (en) | 2011-07-28 | 2012-07-27 | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20130018548A (en) |
-
2012
- 2012-07-27 KR KR1020120082521A patent/KR20130018548A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230105745A1 (en) | Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof | |
JP4053073B2 (en) | Isethionate, a selective CDK4 inhibitor | |
ES2859510T3 (en) | Pyridazinone fused tricyclic compounds useful for treating orthomyxovirus infections | |
AU2022269073A1 (en) | Exatecan derivatives and antibody-drug conjugates thereof | |
AU2012298813B2 (en) | Inhibitors of Nedd8-activating enzyme | |
MX2007013780A (en) | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c. | |
JP2019509990A (en) | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (CHK1) inhibitors, and their preparation and use | |
AU2015330554B2 (en) | Crystal form of bisulfate of JAK inhibitor and preparation method therefor | |
JP6501773B2 (en) | Salt of dasatinib in crystalline form | |
CN112010839B (en) | Crystalline forms of a targeted silk/threonine kinase inhibitor | |
JP2022521081A (en) | Amide derivatives useful in the treatment of HBV infections or HBV-induced diseases | |
US20220389025A1 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
JP2021512922A (en) | Heteroaryl compounds, their pharmaceutical compositions, and their therapeutic use | |
RU2680138C2 (en) | Tricyclic gyrase inhibitors | |
CA2956788A1 (en) | Fumarate analogs and uses thereof in the treatment of an autoimmune disease or an inflammatory disease | |
RU2703454C2 (en) | Dipicolylamine derivatives and pharmaceutical use thereof | |
KR20180085814A (en) | Preparation of Substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine | |
JP2018502851A (en) | Simple synthesis of urea derivatives of amphotericin B | |
WO2021129841A1 (en) | Compound used as ret kinase inhibitor and application thereof | |
US10464883B2 (en) | Compounds and methods for the treatment of neurodegenerative diseases | |
WO2020173417A1 (en) | Acryloyl-containing nuclear transport regulator and uses thereof | |
JP7229482B2 (en) | Novel amide-based compound, and Pin1 inhibitor, therapeutic agent for inflammatory disease, and therapeutic agent for cancer using the same | |
CN108794517B (en) | Arginase inhibitor and preparation method and application thereof | |
KR20130018548A (en) | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide | |
JP2023538638A (en) | Pyrazole boronic acid compounds, pharmaceutical compositions containing the same, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |